[1]王有枝,李彦豪,梅雀林,等.原发性肝癌肝动脉化疗栓塞术后继发溶血性尿毒综合征3例并文献复习[J].介入放射学杂志,2016,(06):543-545.
　WANG You-zhi,LI Yan-hao,MEI Que-lin,et al.Secondary hemolytic uremic syndrome occurring after transcatheter arterial chemoembolization for primary hepatocellular carcinoma: report of 3 cases with literature review [J].journal interventional radiology,2016,(06):543-545.
点击复制

原发性肝癌肝动脉化疗栓塞术后继发溶血性尿毒综合征3例并文献复习 ()

PDF下载中关闭

  1. 1
  2. 2
  3. 3
分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2016年06期
页码:
543-545
栏目:
临床研究
出版日期:
2016-06-25

文章信息/Info

Title:
Secondary hemolytic uremic syndrome occurring after transcatheter arterial chemoembolization for primary hepatocellular carcinoma: report of 3 cases with literature review

作者:
王有枝; 李彦豪; 梅雀林; 刘秋松
Author(s):
WANG You-zhi;  LI Yan-hao;  MEI Que-lin;  LIU Qiu-song
Department of Interventional Radiology, Affiliated Donghua Hospital, Sun yat-sen University, Dongguan, Guangdong Province 523110, China
关键词:
【关键词】肝细胞癌;  溶血性尿毒综合征;  经导管肝动脉化疗栓塞
文献标志码:
A
摘要:
【摘要】目的探讨原发性肝癌在肝动脉化疗栓塞（TACE）术后继发溶血性尿毒综合征（hemolytic-uremic syndrome,HUS）的临床表现特点。方法回顾性分析3例原发性肝癌于术后继发的临床资料,并复习相关文献。 结果3例原发性肝癌行,分别于术后第1、4、6天突发血红蛋白尿,监测间接胆红素显著升高、血红蛋白显著下降,2例伴有急性肾功能损害。本组发病与介入治疗相关,考虑为药物相关性HUS。经治疗后2例病情好转,1例死亡。结论HUS罕见但可能致命,典型临床征象有助于早期识别该疾病,及时采取适当治疗措施可改善预后。


参考文献/References:

［1］Warwicker P. Thrombotic microangiopathies and the kidney［J］. Medicine, 2015, 43: 529-532.

［2］张毓文. 溶血尿毒综合征的诊治进展［J］. 实用儿科临床杂志, 2004, 19： 6-11.

［3］易著文, 张辉. 溶血尿毒综合征发病机制及诊治进展［J］. 实用儿科临床杂志, 2011, 26： 1385-1387.

［4］Salvadori M, Bertoni E. Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations［J］. World J Nephrol, 2013, 2: 56-76.

［5］Pape L, Hartmann H, Bange FC, et al. Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement［J］. Medicine（Baltimore）, 2015, 94: e1000.

［6］El-Ghazal R, Podoltsev N, Marks P, et al. Mitomycin-C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era［J］. Clin Colorectal Cancer, 2011, 10: 142-145.

［7］Malina M, Roumenina LT, Seeman T, et al. Genetics of hemolytic uremic syndromes［J］. Presse Med, 2012, 41: e105-e114.

［8］孟银苹, 付蓉. 补体活化与血栓性微血管病血栓形成关系的研究进展［J］. 中华血液学杂志, 2014, 35： 767-770.

［9］Reese JA, Bougie DW, Curtis BR, et al. Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the Blood Center of Wisconsin［J］. Am J Hematol, 2015, 90: 406-410.

［10］Rafiq A, Tariq H, Abbas N, et al. Atypical hemolytic-uremic syndrome: a case report and literature review［J］. Am J Case Rep, 2015, 16: 109-114.

［11］Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: state of the art［J］. Mol Immunol, 2015, 67: 31-42.

［12］Noris M, Remuzzi G. Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: Core Curriculum 2015［J］. Am J Kidney Dis, 2015, 66: 359-375.

［13］符君, 李小平, 王建六. 复发性卵巢癌化疗相关性溶血性尿毒综合征1例(附文献复习)［J］. 肿瘤预防与治疗, 2008, 21： 409-411.

［14］Mannucci PM. Thrombotic microangiopathies: the past as prologue［J］. Eur J Intern Med, 2013, 24: 484-485.

［15］Iams W, Beckermann KE, Neff AT, et al. Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report［J］. Med Oncol, 2013, 30: 568.

［16］Killian M, Bruel Tronchon N, Maillard N, et al. A diagnosis of haemolytic-uraemic syndrome blurred by alcohol abuse［J］. BMJ Case Rep, 2014, pii: bcr 2014205940.

［17］Racca P, Spadi R, Fora G, et al. Hemolytic uremic syndrome induced by infusion of oxaliplatin: a case report［J］. Tumori, 2011, 97: 31e-33e.

［18］Malkhasyan K, Halene S, Lacy J. Oxaliplatin-related acute disseminated intravascular coagulation syndrome in a patient with metastatic colon cancer［J］. Clin Colorectal Cancer, 2015, 14: e9-e12.

［19］Dinh A, Anathasayanan A, Rubin LM. Safe and effective use of eculizumab in the treatment of severe Shiga toxin Escherichia coli-associated hemolytic uremic syndrome［J］. Am J Health Syst Pharm, 2015, 72: 117-120.

［20］管娜, 刘晓宇, 姚勇, 等. 抗H因子自身抗体相关性溶血尿毒综合征临床特点、治疗及随访［J］. 中华儿科杂志, 2014, 52： 223-226.

 

相似文献/References:

[1]蒋健强,李晓娟,李拥军,等.白蛋白-胆红素评分在预测TACE治疗巨块型肝细胞癌后肝功能衰竭中的应用[J].介入放射学杂志,2023,32(01):55.
　JIANG Jianqiang,LI Xiaojuan,LI Yongjun,et al.The application of albumin-bilirubin score in predicting liver failure after transarterial chemoembolization for massive hepatocellular carcinoma [J].journal interventional radiology,2023,32(06):55.
[2]刘　晟,周平盛,沈　强,等.超声引导下微波消融术治疗特殊部位与非特殊部位单发肝细胞癌的疗效对比[J].介入放射学杂志,2023,32(01):36.
　LIU Sheng,ZHOU Pingsheng,SHEN Qiang,et al.Ultrasound-guided microwave ablation for the treatment of single hepatocellular carcinoma located at specific area and at non-specific area: comparison of clinical efficacy[J].journal interventional radiology,2023,32(06):36.
[3]王　曦,冯　苏,李　红,等.免疫检查点抑制剂联合TACE在肝癌治疗中的研究进展[J].介入放射学杂志,2023,32(01):90.
　WANG Xi,FENG Su,LI Hong,et al.Research progress in immune checkpoint inhibitors combined with TACE for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2023,32(06):90.
[4]吴迪,郑琳.载药微球栓塞治疗在肝癌全程管理中的临床应用进展[J].介入放射学杂志,2024,33(08):921.
　WU Di,ZHENG Lin..Application progress of drug-loaded microspheres embolization therapy in the clinical full-process management of hepatocellular carcinoma[J].journal interventional radiology,2024,33(06):921.
[5]陈荔,吴大广,朱光宇,等.经动脉化疗栓塞联合免疫和靶向药治疗Child-Pugh B级肝细胞癌研究[J].介入放射学杂志,2024,33(09):968.
　CHEN Li,WU Daguang,ZHU Guangyu,et al.Transarterial chemoembolization combined with immune checkpoint inhibitor and molecular targeted therapy for Child-Pugh grade B hepatocellular carcinoma[J].journal interventional radiology,2024,33(06):968.
[6]石佳鹏,汤小星,顾祝新,等.TACE联合瑞戈非尼及PD-1二线序贯治疗中晚期肝细胞癌的临床研究[J].介入放射学杂志,2024,33(09):995.
　SHI Jiapeng,TANG Xiaoxing,GU Zhuxin,et al.TACE combined with regorafenib and PD-1 second-line sequential therapy for advanced hepatocellular carcinoma：a clinical study[J].journal interventional radiology,2024,33(06):995.
[7]张岩基,王汇源,李浩,等.经导管动脉化疗栓塞和肝动脉灌注化疗治疗肝细胞癌现状和进展[J].介入放射学杂志,2024,33(09):1039.
　ZHANG Yanji,WANG Huiyuan,LI Hao,et al.Current status and progress of TACE and HAIC in the treatment of hepatocellular carcinoma[J].journal interventional radiology,2024,33(06):1039.
[8]殷梦杰,付守忠,戴锋,等.肝动脉灌注化疗联合卡瑞利珠单抗及索拉非尼治疗中晚期肝癌的疗效与安全性分析 [J].介入放射学杂志,2024,33(11):1212.
　YIN Mengjie,FU Shouzhong,DAI Feng,et al.Hepatic arterial infusion chemotherapy combined with carrelizumab and sorafenib for the treatment of advanced hepatocellular carcinoma：its clinical efficacy and safety[J].journal interventional radiology,2024,33(06):1212.
[9]杜楠,王英,李文涛.肝癌TACE还是HAIC？[J].介入放射学杂志,2024,33(12):1269.
　DU Nan,WANG Ying,LI Wentao..Treatment of hepatocellular carcinoma：TACE or HAIC？[J].journal interventional radiology,2024,33(06):1269.
[10]张赛锋,王道仁,邵国良.小粒径载药微球在肝细胞癌治疗中的安全性和疗效分析[J].介入放射学杂志,2024,33(12):1373.
　ZHANG Saifeng,WANG Daoren,SHAO Guoliang..Small-size drug-eluting beads TACE for the treatment of hepatocellular carcinoma：its safety and efficacy analysis[J].journal interventional radiology,2024,33(06):1373.

备注/Memo

备注/Memo:
(收稿日期：2015-10-07)


(本文编辑：俞瑞刚)
更新日期/Last Update: 2016-06-21